|
AU2013203788A1
|
|
Dissolution composition for examining drug solubility
|
|
EP2682106A1
|
|
Method of solubilizing biologically active compounds
|
|
EP2645099A1
|
|
Biorelevant compositions
|
|
EP2331070A1
|
|
Method of solubilising biologically active compounds
|
|
GB0915928D0
|
|
Nutrient Compositions
|
|
CA2627945A1
|
|
Dissolution composition for examining drug solubility
|
|
CA2618447A1
|
|
Crystal forms of astaxanthin
|
|
AU2006251391A1
|
|
Direct dissolution
|
|
WO2005110360A2
|
|
Compositions for injection
|
|
EP1626911A2
|
|
Flexible containers
|
|
US2006153886A1
|
|
Ambiphilic porous matrix
|
|
EP1592406A2
|
|
Lipophilic compositions
|
|
WO2004047554A1
|
|
Marine lipid compositions
|
|
AU2003292110A1
|
|
Confectionery composition
|
|
US2006233846A1
|
|
Microdispersion and method of producing same
|
|
WO03063835A1
|
|
Composition comprising low water soluble compounds within porous carriers
|
|
WO03042392A1
|
|
Standardised phospholipid mixtures
|
|
EP1410020A2
|
|
Test system and method suitable for selecting test materials and formulations
|
|
CA2442539A1
|
|
Method and composition for solubilising a biologically active compound with low water solubility
|
|
GB0011724D0
|
|
Pharmaceutical composition for anthelmintics
|
